Heerspink HJ, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al
By contrast, MACE risk was significantly lower among those who continued GLP-1RA use for 2 and 2.5 years, and lowest among those who maintained treatment for three years
This 2024 guidance updates earlier interim recommendations from the American Society of Anesthesiologists (ASA) issued in 2023, which had suggested more routine holding of these medications (daily formulations on the day of procedure, weekly formulations for one week prior)
There is currently no evidence that semaglutide becomes toxic or poisonous after it expires
These policies change frequently, so verification with your state Medicaid office is essential before submitting claims or starting treatment
For patients and adults using GLP-1 medications Download the free GLP-1 Muscle-Preserving Weight-Loss Checklist This patient-friendly guide includes: What to monitor beyond body weight Practical resistance-training and nutrition guidance Strength and function self-checks Hydration and appetite considerations Warning signs to discuss with a clinician A printable monthly tracking page For clinicians Download the GLP-1 Muscle-Preserving Weight-Loss Clinician Companion The clinician companion includes: Baseline risk-screening prompts Strength and function assessment options Protein and kidney-disease considerations Resistance-training counseling Follow-up and referral considerations Documentation language Body-composition and sarcopenia terminology guardrails Claims that should not be overstated These resources are designed to support a more complete weight-loss conversation: not merely how much weight was lost, but whether strength, function, nutrition, and physical resilience were preserved
